21SEP

Apollo's cold vaccine clears Phase 1 dosing

1 min read

16:52UTC

Apollo Therapeutics finished dosing a 144-person trial on 25 August and reports immune responses against all three rhinovirus species from a single shot.

← Back to Nscale takes $103.4bn of contracts to NYSE Jump to analysis ↓

TechnologyDeveloping

Key takeaway

Apollo reports a single dose raising responses against all three rhinovirus species.

Apollo Therapeutics, based in Cambridge, completed dosing on 25 August in a 144-person Phase 1 trial of a vaccine against rhinovirus, the family of viruses behind most common colds ¹. The company reports T-cell responses, meaning white blood cells activating to fight infection, across all three rhinovirus species from a single dose, and no serious adverse events in the first part of the trial.

Vaccine developers have attempted and abandoned a cold vaccine for sixty years for one reason. Rhinovirus comes in many distinct types spread across three species, and an immune response raised against one type has generally done nothing about the rest. A cross-species response from one dose is the claim that decides whether the approach is worth the next stage, and it is precisely what Apollo says it measured.

Two cautions belong alongside it. Immunogenicity data show that the immune system responded, not that anyone caught fewer colds, and the first part of a Phase 1 trial is designed around safety in small numbers rather than efficacy. The readout earns the company its next trial. It does not yet earn a product. Four research funding programmes opened across the base last month, between ARIA, Innovate UK and the national research funder , and none of those calls pays for the larger efficacy trial this result now points towards.

Deep Analysis

In plain English

Apollo Therapeutics is testing an experimental vaccine against the common cold in its first human trial. The trial's first part involved 144 people and found no serious side effects, and blood tests showed the immune system reacted against all three types of rhinovirus (the group of viruses that cause most colds) the vaccine targets. A Phase 1 trial like this one mainly checks whether a vaccine is safe, not whether it actually stops people catching colds. The immune reaction seen here is a promising early sign, but it does not yet prove the vaccine works in practice.

Sources:Apollo Therapeutics

Mentions:Innovate UK →Cambridge →

First Reported In

Update #15 · Nscale takes $103.4bn of contracts to NYSE

Apollo Therapeutics· 21 Sept 2026

Read original →

Different Perspectives

Nscale and Open Cosmos

Nscale chose the New York Stock Exchange for its listing on 18 September, putting Britain's largest AI infrastructure bet to American public investors rather than British ones. Open Cosmos took the opposite route four days earlier, raising nine figures from an all-domestic syndicate on five years of profit, evidence that staying is possible when the balance sheet allows it.

Dame Chi Onwurah and the Science, Innovation and Technology Committee

Committee chair Dame Chi Onwurah wrote to government on 7 September asking how Matt Clifford's conflict at ARIA arose and what safeguards protect its governance, and expects a detailed response. Her question has not yet been put to the Sovereign AI Unit, whose own chair sits at a venture capital firm while overseeing state AI equity.

The Entrepreneurs Network

The Entrepreneurs Network's founder survey found 65% say Britain is easy to start a business in but only 14% say it is easy to scale one, with 82% negative on tax and 74% finding investment hard to access. On this reading the constraint is regulation and tax, not the capital-vehicle design the state keeps adjusting.

New Economics Foundation

The New Economics Foundation argues fiscal accounting rules, not political will, cap what Britain's state capital vehicles can do. Matching the KfW and Bpifrance benchmark of 1% of GDP would need the National Wealth Fund to deploy roughly GBP21bn a year by 2028-29, about four times its current capacity.

Competition and Markets Authority

The CMA's 8 September report on public procurement asked whether Britain's roughly GBP400bn state-spending system is built to grow high-potential firms rather than simply widen SME participation. Its Recommendation 5 calls for a dedicated frontier-technology procurement framework, an official acknowledgement that today's design may serve the wrong target.

Highland Europe

Highland Europe, the growth-equity firm behind a €1bn-plus fund, took €65m from the British Business Bank into its Technology Growth Fund VI on 30 July via British Patient Capital. For a Geneva-based growth investor, the Bank's cheque is routine cornerstone capital, unrelated to which Whitehall department currently claims to sponsor UKRI.